Tarsus Pharmaceuticals (TARS) Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $537.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 11.74% year-over-year to $537.2 million in Q1 2026; TTM through Mar 2026 was $537.2 million, a 11.74% increase from a year earlier, with the FY2025 full-year figure at $522.8 million, up 46.56% from the prior year.
• Current Assets grew to $537.2 million in Q1 2026 per TARS's latest filing, from $522.8 million in the prior quarter.
• Across five years, Current Assets topped out at $537.2 million in Q1 2026 and bottomed at $178.8 million in Q1 2022.
• The 5-year median for Current Assets is $340.7 million (2024), against an average of $337.1 million.
• Across the five-year window, Current Assets slipped 26.69% in 2023 and surged 97.62% in 2024, its largest moves.
• Year by year, Current Assets stood at $225.4 million in 2022, then rose by 13.65% to $256.1 million in 2023, then jumped by 39.27% to $356.7 million in 2024, then soared by 46.56% to $522.8 million in 2025, then rose by 2.76% to $537.2 million in 2026.
• Per Business Quant, the three latest TARS Current Assets figures stand at $537.2 million (Q1 2026), $522.8 million (Q4 2025), and $501.7 million (Q3 2025).